… with no serious adverse events QR-421a is the second ophthalmology program where clinical activity was predicted … benefit was observed across multiple relevant measures appropriate to the severity of the patient’s disease, … treated eye, <5 dB.steradian change in untreated eye], and optical coherence tomography (OCT) assessment of …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects … Brompton Hospital, and immediate past-president of the European Cystic Fibrosis Society, added, “QR-010 exceeded … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow ® is a …